Biotest Balance Sheet Health
Financial Health criteria checks 1/6
Biotest has a total shareholder equity of €351.1M and total debt of €650.9M, which brings its debt-to-equity ratio to 185.4%. Its total assets and total liabilities are €1.2B and €839.1M respectively.
Key information
185.4%
Debt to equity ratio
€650.90m
Debt
| Interest coverage ratio | n/a |
| Cash | €68.00m |
| Equity | €351.10m |
| Total liabilities | €839.10m |
| Total assets | €1.19b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BIO3D's short term assets (€597.4M) exceed its short term liabilities (€129.5M).
Long Term Liabilities: BIO3D's short term assets (€597.4M) do not cover its long term liabilities (€709.6M).
Debt to Equity History and Analysis
Debt Level: BIO3D's net debt to equity ratio (166%) is considered high.
Reducing Debt: BIO3D's debt to equity ratio has increased from 138.6% to 185.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BIO3D has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BIO3D has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.